RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $25.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $0.00.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-06-30 was $1.84M.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-03-31 was $54.96K.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-03-31 was $148.00B.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $1.30T.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 0 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 2 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 2 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $25.00K 10-Q · filed 2026-08-06 | |||||||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.84M derived: sum of 2 quarters · filed 2025-11-13 | $1.89M 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.89M 10-Q · filed 2025-08-07 | ||||||||
| 2025-03-31 | $54.96K 10-Q · filed 2025-05-12 | |||||||||
| 2024-12-31 | $1.30T 10-K · filed 2025-03-27 | |||||||||
| 2024-06-30 | $1.30M 10-Q · filed 2024-08-07 | |||||||||
| 2023-12-15 | $10.70M 10-K · filed 2025-03-27 | |||||||||
| 2023-09-18 | $23.84K 10-K · filed 2025-03-27 | |||||||||
| 2023-06-20 | $148.42K 10-K · filed 2025-03-27 | $148.42B 10-K · filed 2024-03-19 | ||||||||
| 2023-03-31 | $148.00B 10-Q · filed 2024-05-08 | |||||||||
| 2023-02-21 | $1.93M 10-K · filed 2025-03-27 | |||||||||
| 2022-09-29 | $5.00M 10-K · filed 2024-03-19 | $5.00 10-K · filed 2023-03-23 | ||||||||
| 2022-05-25 | $4.60M 10-K · filed 2023-03-23 | |||||||||
| 2022-05-05 | $4.60M 10-K · filed 2024-03-19 | |||||||||
| 2022-03-28 | $307.85K 10-Q · filed 2022-05-05 | $307.85K 10-K · filed 2024-03-19 | $307.85K 10-K · filed 2023-03-23 | |||||||
| 2022-03-14 | $1.60M 10-K · filed 2024-03-19 | |||||||||
| 2021-12-17 | $81.60 10-K · filed 2023-03-23 | |||||||||
| 2021-07-16 | $10.24M 10-Q · filed 2021-11-12 | |||||||||
| 2021-07-12 | $212.22K 10-Q · filed 2021-11-12 | |||||||||
| 2021-06-25 | $211.65K 10-Q · filed 2021-08-10 | $211.65K 10-Q · filed 2021-11-12 | ||||||||
| 2021-06-18 | $190.40K 10-Q · filed 2021-08-10 | $190.40K 10-Q · filed 2021-11-12 | ||||||||
| 2021-02-18 | $701.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |